
Contact & links
2525, Chemin de la Canardière,
Porte A-1-2
Québec, Canada
G1J 2G3
Marc-André Roy
MD, MSc (epidemiology), FRCP
Full professor, Department of Psychiatry and Neurosciences, Faculté de Médecine de l’Université Laval
Director, RAPPSoDIS Lab and CAP-Rétablissement Research Teams, Centre de Recherche CERVO
Psychiatrist and medical director, Clinique Notre-Dame des Victoires (Institut universitaire de Santé mentale de Québec du Centre intégré universitaire de Santé et Services sociaux de la Capitale nationale)
Research axis:
Clinical and Cognitive Neuroscience
Innovative approaches to treating psychosis and schizophrenia
Dr. Marc-André Roy is a psychiatrist and a clinical scientist. His research focuses on schizophrenia , particularly early psychosis. He is among the pionneers and leaders in Québec and Canada in this field in which he has worked without interruption since 1997, which was aknowledged with the Heinz Lehman award of the AMPQ that recognizes lifetime contribution to psychiatry . He is also interested in the disorders that are often associated with these psychotic disorders, including anxiety disorders, substance use disorders as well as pathological gambling.
The goal of Dr. Roy’s research is to develop, test and compare new approaches to treat psychotic disorders mostly in a real-life setting, within a recovery-oriented approach. He is interested in the treatments currently given to patients to optimize their use, within a recovery-oriented approach.
Regarding pharmacological treatments, he is conducting studies of the impact of long-acting injectable antipsychotics and clozapine in a real-life clinical setting, including the management of their side-effects. He also uses large population registries to examine the impact of these treatments as well as the patterns of their use. In addition to comparing pharmacological methods, Dr. Roy has also been involved in studies to determine the efficacy of various other non-pharmacological approaches, such as cognitive remediation or cognitive-behavioral psychotherapy.
Dr. Marc-André Roy’s research is helping to develop new intervention strategies adapted to patients, according to their diagnosis and associated disorders, and whose effectiveness is demonstrated in daily practice. He is passionately committed to promoting the recovery of these individuals and supporting their families, particularly through the FRQ-SC CAP-Recovery Research Group and through his knowledge transfer activities, that include the development of the website Projet-rétablissement.
Doctor Roy is a psychiatrist and a clinical scientist whose project focuses on schizophrenia and related psychoses, particularly on the development and assessment of new approaches in the treatment of early psychoses and on a better understanding of the comorbidity within psychosis disorders. Most of his research and clinical activities take place at the Clinique Notre-Dame des Victoires, an early intervention program for psychotic disorder (CIUSSS-Capitale Nationale).
Dr Roy has completed his training in medicine and psychiatry (1991) at Laval University. He then completed a three-year fellowship in epidemiology and genetics research on psychotic disorders at University of Iowa, with Drs Nancy Andreasen and Raymond Crowe, and then in genetic epidemiology at the Medical College of Virginia with Dr Kenneth Kendler.
Since then, he has been a clinical-scientist at the centre de recherche de l’Institut universitaire en Santé Mentale de Québec (IUSMQ). He is a professor of Psychiatry and Neurosciences at the Faculté de Médecine de l’Université Laval, where he chairs the research committee of the psychiatric residency program. He is also a clinical psychiatrist at the Clinique Notre-Dame-des-Victoires of the IUSMQ, an early intervention program dedicated to young adults at an early stage of a psychotic disorder, with a special emphasis on recovery-based interventions and collaboration with families. He has published over a hundred of scientific papers in peer-reviewed journals and his work has been supported by several agencies, including the Canadian Institutes of Health Research. He is supervising or has supervised over 20 graduate students (from various disciplines) and psychiatric residents.
2015 : Prix Hippocrate: prize acknowledging physicians and pharmacists’ collaboration, from the magazine «Le patient».
2014: First award for the book «Je suis une personne, pas une maladie», Institut Universitaire en santé mentale du Québec.
2011 : First award for the project : «Anxiety disorders and psychosis», Institut Universitaire en santé mentale du Québec.
Publications
Maxime Huot-Lavoie; Olivier Cobeil; Olivier Roy; Sophie L’Heureux; Magali Dufour; Josiane Lavallée; Laurent Béchard; Sébastien Brodeur; Marie-France Demers; Marc-André Roy; Yasser Khazaal
Integrating gaming disorder into early intervention in first-episode psychosis – current knowledge and future directions Journal Article
In: Ir J Psychol Med, pp. 1–10, 2025, ISSN: 2051-6967.
@article{pmid41362155,
title = {Integrating gaming disorder into early intervention in first-episode psychosis - current knowledge and future directions},
author = {Maxime Huot-Lavoie and Olivier Cobeil and Olivier Roy and Sophie L'Heureux and Magali Dufour and Josiane Lavallée and Laurent Béchard and Sébastien Brodeur and Marie-France Demers and Marc-André Roy and Yasser Khazaal},
doi = {10.1017/ipm.2025.10150},
issn = {2051-6967},
year = {2025},
date = {2025-12-01},
journal = {Ir J Psychol Med},
pages = {1--10},
abstract = {Gaming disorder (GD) is increasingly recognized as a clinically significant condition, yet its implications in first-episode psychosis (FEP) remain largely unexplored. This perspective article focuses on the intersection of GD and FEP, highlighting key diagnostic and treatment challenges, including symptom overlap that complicates differential diagnosis, the absence of validated screening tools, and difficulties in sustained patient engagement. Drawing insights from substance use disorder management in FEP, we propose a preliminary clinical framework for integrating GD assessment and intervention into early intervention in psychosis programs. This approach prioritizes comprehensive evaluation, patient-centered care, and a harm-reduction model that supports digital well-being. Addressing GD inFEP populations is crucial for optimizing functional recovery and promoting a holistic, recovery-oriented approach to psychiatric care. Further research is needed to refine screening tools and validate tailored interventions in this population.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Beatrice Todesco; Srividya N Iyer; Manuela Ferrari; Marc-André Roy; Marie-Hélène Morin; Julie Marguerite Deschênes; Camille Arbaud; Gabriel Julien; Annie Bossé; Mary Anne Levasseur; Amal Abdel-Baki
In: Early Interv Psychiatry, vol. 19, no. 10, pp. e70092, 2025, ISSN: 1751-7893.
@article{pmid41087831,
title = {Using a Learning Health System to Integrate Peer Support in Early Intervention Services for Psychosis in Quebec: Protocol for a Participatory, Mixed-Methods Study (the PAIRPEP Project)},
author = {Beatrice Todesco and Srividya N Iyer and Manuela Ferrari and Marc-André Roy and Marie-Hélène Morin and Julie Marguerite Deschênes and Camille Arbaud and Gabriel Julien and Annie Bossé and Mary Anne Levasseur and Amal Abdel-Baki},
doi = {10.1111/eip.70092},
issn = {1751-7893},
year = {2025},
date = {2025-10-01},
journal = {Early Interv Psychiatry},
volume = {19},
number = {10},
pages = {e70092},
abstract = {INTRODUCTION: Since 2019, SARPEP (Système Apprenant Rapide pour les programmes de Premiers Épisodes Psychotiques), a rapid learning health system (RLHS) for Quebec's Early Intervention for Psychosis Services, operates to bridge the evidence-practice gap across the province. Despite strong stakeholder support and government recommendations, peer support services remained poorly available. To address this gap, since 2023, the PAIRPEP project was co-developed to support and evaluate the implementation of peer support and family peer support. This paper describes the co-designed study protocol, embedded within this RLHS.nnMETHODS: This participatory, mixed-methods study aims to examine the implementation of the PAIRPEP intervention longitudinally over 3 years across 12 Early Intervention Services and its impact on multiple stakeholders. Informed by the Medical Research Council framework for complex interventions, the project includes a co-designed (with multiple stakeholders) multimodal capacity-building program with specific components developed to overcome barriers to integrating peer support and family peer support. Quantitative questionnaires are collected every 4 months from clinicians while youth and families can complete surveys at any convenient time, via QR codes available in clinics, through the RLHS electronic platform. Focus groups are conducted annually over 3 years with eight stakeholder groups. The analysis integrates findings using thematic synthesis and joint displays to assess convergence and divergence across methods and perspectives.nnRESULTS AND CONCLUSION: This protocol paper outlines the study's co-design, procedures and anticipated contributions. Embedding large-scale innovative intervention implementation (such as peer support) within an RLHS can foster real-time feedback, iterative refinement and inform clinical practice and policies.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Laurent Béchard; Elizabeth Anderson; Olivier Corbeil; Maxime Huot-Lavoie; Sébastien Brodeur; Amal Abdel-Baki; Charles Massé; Mina Gabriel-Courval; Marie-Ève Coté; Annie LeBlanc; Marc-André Roy; Marie-France Demers; Sophie Lauzier
In: BJPsych Open, vol. 11, no. 5, pp. e193, 2025, ISSN: 2056-4724.
@article{pmid40904211,
title = {Factors shaping the decision-making process to continue or discontinue antipsychotics: exploratory qualitative study of 12 individuals in remission from first-episode psychosis},
author = {Laurent Béchard and Elizabeth Anderson and Olivier Corbeil and Maxime Huot-Lavoie and Sébastien Brodeur and Amal Abdel-Baki and Charles Massé and Mina Gabriel-Courval and Marie-Ève Coté and Annie LeBlanc and Marc-André Roy and Marie-France Demers and Sophie Lauzier},
doi = {10.1192/bjo.2025.10817},
issn = {2056-4724},
year = {2025},
date = {2025-09-01},
journal = {BJPsych Open},
volume = {11},
number = {5},
pages = {e193},
abstract = {BACKGROUND: The decision-making process regarding antipsychotic continuation or discontinuation following remission from first-episode psychosis (FEP) remains complex and underresearched. While discontinuation increases the risk of relapse, concerns over long-term side-effects such as metabolic disturbances and extrapyramidal symptoms also exist. Current guidelines recommend maintaining antipsychotics for 1-5 years, emphasising shared decision-making (SDM) between clinicians and patients.nnAIMS: This study aimed to explore the decision-making process and describe the factors influencing the decision to discontinue or continue antipsychotic treatment following remission from FEP, from the patients' perspective.nnMETHOD: A descriptive qualitative study was conducted with 12 individuals in remission from FEP who received care at early intervention services in Quebec, Canada. Data were collected through online semi-structured interviews and analysed thematically to identify key factors influencing treatment decisions.nnRESULTS: The decision-making process was activated by treatment reflection triggers and shaped by various perceptions (of illness, treatment and stigma) and relationships (with friends, family and the clinical team), ultimately leading to decisions to either discontinue, continue (at standard or reduced dose) or remain ambivalent. This dynamic process was guided by participants' motivators, such as well-being and societal contribution. Most participants felt that discontinuation discussions were not initiated by the clinical team.nnCONCLUSIONS: The decision-making process is driven by motivators that were found to be linked to the concept of personal recovery. This study highlights the need for proactive, personalised discussions between clinicians and patients. Future research should focus on decision aids tailored to the FEP population to support SDM and improve treatment outcomes.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Audrey Cayouette; Caroline Cellard; Marion Fossard; Dominique Knutsen; Marc-André Roy; Maxime Rancourt; Stéphanie D’Amours; Rose Bourget; Laurie Bolduc; Amelie Achim
In: Philos Trans R Soc Lond B Biol Sci, vol. 380, no. 1932, pp. 20230506, 2025, ISSN: 1471-2970.
@article{pmid40808461,
title = {Being well understood and generating interest during verbal interactions: the role of Theory of Mind and clinical symptoms in people with schizophrenia spectrum disorders},
author = {Audrey Cayouette and Caroline Cellard and Marion Fossard and Dominique Knutsen and Marc-André Roy and Maxime Rancourt and Stéphanie D'Amours and Rose Bourget and Laurie Bolduc and Amelie Achim},
doi = {10.1098/rstb.2023.0506},
issn = {1471-2970},
year = {2025},
date = {2025-08-01},
journal = {Philos Trans R Soc Lond B Biol Sci},
volume = {380},
number = {1932},
pages = {20230506},
abstract = {People with schizophrenia spectrum disorders (SSD) present with communication impairments. This study aimed to determine whether individuals with SSD make it less easy or interesting to perform a joint task with them relative to community controls (CO), and to examine the link between clinical symptoms and theory of mind (ToM). Fifty-one outpatients with SSD and 68 CO performed the storytelling in sequence task (STST) with an interaction partner. Four raters subsequently listened to the STST audio recordings and scored how easily they could place the images of the narrated stories in the correct order (Facility ratings), how interesting they found the stories (Interest ratings) and how expressive they found the voice (Expressivity ratings). Symptoms were assessed using the Positive and Negative Syndrome Scale and ToM using the Combined Stories Test. The Facility, Interest and Expressivity ratings were lower in SSD than in CO. In SSD, the Facility ratings were positively associated with ToM and negatively associated with several symptom dimensions. The Interest and Expressivity ratings were strongly linked together and negatively associated with Negative symptoms. ToM deficits in SSD may contribute to difficulties communicating clearly. The strong association between Expressivity and Interesting ratings raises important questions regarding the real-life impacts of reduced expressivity.This article is part of the theme issue 'At the heart of human communication: new views on the complex relationship between pragmatics and Theory of Mind'.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Stephanie Coronado-Montoya; Amal Abdel-Baki; Paule Bodson-Clermont; David Boucher-Roy; José Côté; Candice E Crocker; David Crockford; Jean-Gabriel Daneault; Simon Dubreucq; Maxime Dussault-Laurendeau; Benedikt Fischer; Pamela Lachance-Touchette; Tania Lecomte; Sophie L’Heureux; Clairélaine Ouellet-Plamondon; Marc-André Roy; Ovidiu Tatar; Philip G Tibbo; Marie Villeneuve; Anne Wittevrongel; Didier Jutras-Aswad
In: Psychiatry Res, vol. 350, pp. 116553, 2025, ISSN: 1872-7123.
@article{pmid40450961,
title = {A pilot randomized controlled trial of a digital cannabis harm reduction intervention for young adults with first-episode psychosis who use cannabis},
author = {Stephanie Coronado-Montoya and Amal Abdel-Baki and Paule Bodson-Clermont and David Boucher-Roy and José Côté and Candice E Crocker and David Crockford and Jean-Gabriel Daneault and Simon Dubreucq and Maxime Dussault-Laurendeau and Benedikt Fischer and Pamela Lachance-Touchette and Tania Lecomte and Sophie L'Heureux and Clairélaine Ouellet-Plamondon and Marc-André Roy and Ovidiu Tatar and Philip G Tibbo and Marie Villeneuve and Anne Wittevrongel and Didier Jutras-Aswad},
doi = {10.1016/j.psychres.2025.116553},
issn = {1872-7123},
year = {2025},
date = {2025-08-01},
journal = {Psychiatry Res},
volume = {350},
pages = {116553},
abstract = {Cannabis use is widespread and associated with worsened prognosis for young adults with first-episode psychosis (FEP). Few cannabis harm reduction interventions have been evaluated for this population, despite potential to improve outcomes in those not ready for cannabis abstinence/reduction-focused interventions. This study aimed to determine a) the acceptability of a digital harm reduction intervention, the Cannabis Harm-reducing App to Manage Practices Safely (CHAMPS) and b) the feasibility of conducting a trial comparing FEP-specialized early intervention services (EIS)+CHAMPS versus EIS-only with this population. We conducted a multi-site pilot randomized controlled trial comparing both arms in 101 young adults (18 - 35 years old) with FEP using cannabis and attending EIS. Primary outcomes were trial retention rate (i.e., proportion of randomized participants retained at week 6; trial feasibility assessment) and CHAMPS completion rate (i.e., proportion of intervention participants completing four of six modules; CHAMPS acceptability assessment). Trial retention rate above 60 % indicated feasibility and completion rate above 50 % indicated acceptability. Additional outcomes included harm reduction strategy use, motivation to change cannabis behaviors, cannabis-related problems, cannabis use, psychotic symptoms and dependence severity, assessed at baseline, weeks 6, 12 and 18. Trial retention was 82.2 % and completion rate was 58.8 %, suggesting trial feasibility and CHAMPS acceptability. Signals of possible improvement in the intervention group were observed regarding harm reduction strategy use, motivation to change behaviors, cannabis-related problems and cannabis use frequency. This study supports conducting an efficacy trial assessing the potential of CHAMPS in improving outcomes for young adults with psychosis using cannabis.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Maxime Huot-Lavoie; Laurent Béchard; Olivier Corbeil; Olivier Roy; Sophie L’Heureux; Ingrid Salvini; Catherine Lehoux; Anne-Marie Essiambre; Chantale Thériault; Sébastien Brodeur; Marie-France Demers; Yasser Khazaal; Marc-André Roy
Lived experience of gaming disorder among people with psychotic disorders: implications for tailored interventions and clinical management Journal Article
In: Curr Opin Psychiatry, vol. 38, no. 4, pp. 295–301, 2025, ISSN: 1473-6578.
@article{pmid40403141,
title = {Lived experience of gaming disorder among people with psychotic disorders: implications for tailored interventions and clinical management},
author = {Maxime Huot-Lavoie and Laurent Béchard and Olivier Corbeil and Olivier Roy and Sophie L'Heureux and Ingrid Salvini and Catherine Lehoux and Anne-Marie Essiambre and Chantale Thériault and Sébastien Brodeur and Marie-France Demers and Yasser Khazaal and Marc-André Roy},
doi = {10.1097/YCO.0000000000001013},
issn = {1473-6578},
year = {2025},
date = {2025-07-01},
journal = {Curr Opin Psychiatry},
volume = {38},
number = {4},
pages = {295--301},
abstract = {PURPOSE OF REVIEW: Despite growing recognition of the impact of Gaming Disorder in individuals with psychotic disorders, little is known about the clinical and personal implications of this dual diagnosis. Preliminary data suggest that Gaming Disorder may be associated with increased psychotic symptoms and reduced occupational and social functioning. However, insight from lived experience remain largely absent, despite their importance.nnRECENT FINDINGS: This review synthesizes recent literature on the comorbidity between Gaming Disorder and psychotic disorders, highlighting the scarcity of research in this emerging field. It also presents preliminary findings from an ongoing qualitative study focussing on the lived experiences of individuals receiving early psychosis intervention. These data focus on participants' motivations for gaming and their perceptions of both positive and negative effects gaming has on their life.nnSUMMARY: This review underscores the significant lack of data on the dual diagnosis of Gaming Disorder and psychosis. Early qualitative insights reveal diverse gaming motivations, including symptom regulation, anxiety management, cognitive stimulation, and social connection. These first-person accounts emphasize the functional role of gaming and the need for recovery-oriented care. Integrating lived experience into research and clinical practice can improve relevance, support nuanced interventions, and advance our understanding of behavioral addictions in early psychosis.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Amélie M Achim; Dominique Knutsen; Marc-André Roy; Souleymane Gadio; Marion Fossard
In: Schizophr Res Cogn, vol. 40, pp. 100343, 2025, ISSN: 2215-0013.
@article{pmid39867750,
title = {Use of reference markers in the speech of people with schizophrenia spectrum disorders: Evidence from two referential communication tasks manipulating common ground with the interaction partner},
author = {Amélie M Achim and Dominique Knutsen and Marc-André Roy and Souleymane Gadio and Marion Fossard},
doi = {10.1016/j.scog.2024.100343},
issn = {2215-0013},
year = {2025},
date = {2025-06-01},
journal = {Schizophr Res Cogn},
volume = {40},
pages = {100343},
abstract = {INTRODUCTION: People with schizophrenia spectrum disorders present with language dysfunctions, yet we know little about their use of reference markers (indefinite markers, definite markers, pronouns or names), a fundamental aspect of efficient speech production.nnMETHODS: Twenty-five (25) participants with a recent-onset schizophrenia spectrum disorder (SZ) and 25 healthy controls (HC) completed two referential communication tasks. The tasks involved presenting to an interaction partner a series of movie characters (character identification task) and movie scenes composed of six images (narration task). A manipulation was introduced such that half of the movies could be considered as Likely-Known by the interaction partner, whereas the other half was Likely-Unknown. The analyses focused on the reference markers used to present the movie characters during the tasks.nnRESULTS: During the character identification task, the SZ group used fewer names and more pronouns than the HC. During the narration task, the SZ group used fewer names and more definite references when initially introducing the main story characters, while no group effect emerged for subsequent mentions of the characters. The observed effects of conditions were generally present across both groups, except for a lesser adjustment in the use of definite markers when introducing the story characters.nnCONCLUSIONS: While some group differences emerged, people with SZ were generally sensitive to the manipulation regarding their interaction partner's likely knowledge of the characters. A better understanding of the conditions in which speech production is affected in SZ could help promote more efficient communication.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Amal Abdel-Baki; Manuela Ferrari; Annie Leblanc; Camille Arbaud; Daniel Rabouin; Marc-André Roy; Srividya N Iyer
In: Schizophr Res, vol. 277, pp. 20–30, 2025, ISSN: 1573-2509.
@article{pmid39983366,
title = {SARPEP, a rapid-learning healthcare system of early intervention services for psychosis in Quebec, Canada: Feasibility, acceptability and early impacts},
author = {Amal Abdel-Baki and Manuela Ferrari and Annie Leblanc and Camille Arbaud and Daniel Rabouin and Marc-André Roy and Srividya N Iyer},
doi = {10.1016/j.schres.2025.02.001},
issn = {1573-2509},
year = {2025},
date = {2025-03-01},
journal = {Schizophr Res},
volume = {277},
pages = {20--30},
abstract = {INTRODUCTION: Despite growing interest in learning health systems, their application and evaluation in mental health have been scarce. This study aimed to evaluate the feasibility, acceptability and early impacts of SARPEP, a rapid learning healthcare system (RLHS) for early intervention services for psychosis in Quebec, Canada.nnMETHODS: SARPEP comprised technology-supported monitoring of program and patient outcomes, feedback and capacity-building. It involved 11 services (128 professionals, 1700+ patients). We descriptively analyzed quantitative data on the RE-AIM framework (Reach, Effectiveness, Adoption, Implementation, Maintenance) collected in the first two years.nnRESULTS: Reach: Patient and family partners, all programs (clinicians, managers), government representatives and the provincial early psychosis association agreed to co-design and implement all SARPEP components.nnEFFECTIVENESS: Data informed program- and provincial-level decision-making. Some quality indicators (e.g., timely access) improved over time. 80 % of youth were satisfied with services. Adoption: All programs collected data on satisfaction and quality, with data collection improving over time. Eight programs and all stakeholder groups participated in most community-of-practice sessions.nnIMPLEMENTATION: The time required for data collection and providing feedback decreased over time. SARPEP offered rapid, flexible support; tools; and a community of practice that facilitated collecting data, and monitoring and improving practices. Maintenance: All programs remained in SARPEP post study.nnCONCLUSION: Involving all stakeholders, RLHSs can be deployed, adopted, and maintained in mental healthcare and increase the measurement of practices and quality improvement efforts. Strategies are needed to increase the completion of patient-reported measures and to rigorously evaluate the RLHS' effectiveness in improving service quality and outcomes.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Manuela Ferrari; Marianne-Sarah Saulnier; Srividya N Iyer; Marc-André Roy; Amal Abdel-Baki
In: Health Res Policy Syst, vol. 23, no. 1, pp. 34, 2025, ISSN: 1478-4505.
@article{pmid40087675,
title = {Implementing a rapid-learning health system in early intervention services for psychosis: qualitative evaluation of its feasibility and acceptability},
author = {Manuela Ferrari and Marianne-Sarah Saulnier and Srividya N Iyer and Marc-André Roy and Amal Abdel-Baki},
doi = {10.1186/s12961-024-01281-w},
issn = {1478-4505},
year = {2025},
date = {2025-03-01},
journal = {Health Res Policy Syst},
volume = {23},
number = {1},
pages = {34},
abstract = {BACKGROUND: Heterogeneity in implementing essential evidence-based early intervention for psychosis services (EIS) components persists despite existing fidelity standards/guidelines in many countries. Rapid-learning health systems (RLHS) may remedy these challenges, improving service delivery through systematic data collection, analysis, feedback and capacity-building activities. SARPEP (Système Apprenant Rapide pour les Programmes de Premiers Épisodes Psychotiques) is the first Canadian RLHS for EIS. This paper presents qualitative findings from the mixed-method study that evaluated the feasibility and acceptability of SARPEP.nnMETHODS: We conducted six focus groups on the implementation of SARPEP with 25 participants from all SARPEP stakeholder groups; most were involved from project inception and throughout the 3-year implementation. The Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) framework (Glasgow, et al., 2019) and Lessard's dimensions for learning health systems guided data collection and deductive analysis.nnRESULTS: Reach: focus group participants reflected SARPEP reach and included all stakeholders involved (six service users, two family members, four psychiatrists, six managers, seven team leaders) who shared their experiences.nnEFFECTIVENESS: participants confirmed that SARPEP improved program capacity for data collection on core indicators and promoted evidence-based practices. Adoption: participants supported the selection of specific indicators and need to improve data-gathering technologies in the RLHS, even while challenges persisted regarding the integration of digital platform use by service users into routine care. Implementation and maintenance: all participants credited the RLHS with enabling mutual learning, self-reflection of programs and shared improvement of practices.nnCONCLUSIONS: SARPEP contributes to promote evidence-based care and a sense of belonging within the Quebec EIS network.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Candice E Crocker; Thomas Hastings; Marc-Andre Roy; Nicola Otter; Philip G Tibbo
In: Ther Adv Psychopharmacol, vol. 15, pp. 20451253251384509, 2025, ISSN: 2045-1253.
@article{pmid41122435,
title = {Real-world examination of the rates of long-acting injectable attrition in a cohort of early psychosis patients after discharge from an early intervention service for psychosis},
author = {Candice E Crocker and Thomas Hastings and Marc-Andre Roy and Nicola Otter and Philip G Tibbo},
doi = {10.1177/20451253251384509},
issn = {2045-1253},
year = {2025},
date = {2025-01-01},
journal = {Ther Adv Psychopharmacol},
volume = {15},
pages = {20451253251384509},
abstract = {BACKGROUND: Patients treated in early intervention for psychosis programs have better treatment outcomes and higher rates of long-acting injection (LAI) antipsychotic medication utilization (20%-50%) versus treatment as usual. These programs usually serve patients for 2-3 years, then most patients are discharged to other mental health services and studies of patients with longer-standing schizophrenia suggest switching to oral medications may be common. However, following patients post-discharge is complicated by the challenges of migrated patient records across clinical services and providers.nnOBJECTIVES: To examine whether LAI use continues after discharge from an early intervention service for psychosis.nnDESIGN: This study was a retrospective cohort study examining the effects of continuation or discontinuation of LAI therapy in individuals who have completed treatment in an early intervention service (EIS) for psychosis.nnMETHODS: A retrospective cohort was created from a group of individuals discharged from EIS for psychosis over a 3-year period from January 1, 2016 to December 31, 2018 and followed for mental health outcomes and antipsychotic medications prescribed for a subsequent 2-year period at discharge, 6, 12, 18, and 24 months post-discharge.nnRESULTS: Of 85 subjects discharged from three sites in three different provinces in Canada for whom full follow-up could be recorded, 60 subjects remained on LAI medications after 24 months (71%). The average age of the cohort was 22 years (SD 4.7) at admission to an EIS. At discharge, the most commonly used LAI was aripiprazole, and most subjects were maintained on the same formulation at 24 months, if still on LAI. Reasons for discontinuation were predominantly patient preference. Significant differences in clinical outcomes, measured through reduced rehospitalization were seen for those who remained on LAI as compared to those who did not.nnCONCLUSION: LAI adherence is still strong 24 months after discharge from an EIS for psychosis.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
News
CAP-Rétablissement group FRSQSC grant renewal
Robert W Kerwin prize given to the RAPPSODIS laboratory !
Interview with Dr Marc-André Roy in Le Soleil
Psychosis drug may increase risk of problem gambling
Marc-André Roy receives the Heinz E. Lehmann Excellence in Psychiatry prize
CervoTUBE video: Anne-Marie Essiambre





